Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma

J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11.
No abstract available

Keywords: advanced melanoma; clearance; exposure-response; nivolumab; overall survival; population pharmacokinetics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / blood
  • Antineoplastic Agents, Immunological / therapeutic use
  • Bayes Theorem
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase III as Topic
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Melanoma / blood*
  • Melanoma / drug therapy*
  • Melanoma / mortality
  • Middle Aged
  • Nivolumab / adverse effects
  • Nivolumab / blood*
  • Nivolumab / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Survival Rate

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab